阴性夜间血红蛋白尿症:当前的治疗方法,未满足的需求和建议
Monika Oliver1, Christopher J Patriquin2
1Department of Medicine, University of Alberta; Division of Hematology, University of Alberta Hospital, Edmonton, Alberta, Canada.
Journal of blood medicine
|December 12, 2023
概括
阴性夜间血红蛋白尿 (PNH) 是一种罕见的血液疾病. 新的补充抑制剂提供了更好的结果,但突破性血液溶解和治疗坚持等挑战仍然存在.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 罕见疾病 罕见疾病
背景情况:
- 性夜间血红蛋白尿 (PNH) 是一种极为罕见的获得性克隆性疾病.
- PNH导致补充介导的血液细胞的破坏,导致溶血性贫血症,血栓症和末端器官损伤.
- 没有治疗的死亡率约为35%.
研究的目的:
- 审查PNH疗法的当前景观.
- 突出未满足的需求和PNH管理的未来方向.
- 引入全球PNH注册表的开发.
主要方法:
- 审查已批准和正在研究的PNH治疗方法.
- 讨论临床挑战和管理策略.
- 计划的国际PNH注册表的描述.
主要成果:
- 针对性治疗,包括抗C5,抗C3和近位补体抑制剂,改善了患者的治疗结果.
- 有可用的eculizumab生物类似药,扩大了治疗选择.
- 靠近抑制剂对C5抑制的残留性贫血患者有希望.
结论:
- 尽管取得了进展,但在管理突破性血液溶解,外血管血液溶解,怀孕和感染风险方面仍然存在挑战.
- 与自我治疗相关的坚持和风险需要注意.
- 一个集中的国际注册表对于新的PNH疗法和临床挑战的数据收集和分析至关重要.
相关概念视频
Esophageal Varices-II: Clinical Features and Management
71
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
71
Blood Transfusion and Agglutination
10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Hematopoiesis
5.3K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
708
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
708


